Humacyte Stock Performance
| HUMA Stock | USD 4.51 0.14 3.01% |
The company retains a Market Volatility (i.e., Beta) of 2.69, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Humacyte will likely underperform. At this point, Humacyte has a negative expected return of -0.11%. Please make sure to check out Humacyte's skewness, and the relationship between the treynor ratio and daily balance of power , to decide if Humacyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's primary indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.01) | Five Day Return (21.97) | Year To Date Return 56.06 | Ten Year Return (53.36) | All Time Return (53.36) |
1 | Humacyte to Present Efficacy and Safety Results from V007 Phase | 11/22/2024 |
2 | HUMACYTE ALERT Bragar Eagel Squire, P.C. ... | 11/26/2024 |
3 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in ... | 12/05/2024 |
4 | Glancy Prongay Murray LLP Reminds Investors of Looming Deadline in the Class Action ... | 12/12/2024 |
5 | Both individual investors who control a good portion of Humacyte, Inc. along with institutions must be dismayed after last weeks 9.1 percent decrease | 12/13/2024 |
6 | Investors in Humacyte, Inc. Should Contact Levi Korsinsky Before January 17, 2025 to ... | 12/16/2024 |
7 | Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.s market cap dropped by US60m | 12/18/2024 |
8 | Levi Korsinsky Notifies Humacyte, Inc. ... | 12/19/2024 |
9 | Spotlight on Humacyte Analyzing the Surge in Options Activity | 12/20/2024 |
10 | Humacyte Price Target Raised to 17.00 at Benchmark | 12/23/2024 |
11 | HUMA Lead Plaintiff Deadline Approaching -- Contact Robbins LLP for Information About the Class ... | 12/24/2024 |
| Begin Period Cash Flow | 149.8 M | |
| Free Cash Flow | -75.6 M |
Humacyte |
Humacyte Relative Risk vs. Return Landscape
If you would invest 547.00 in Humacyte on September 26, 2024 and sell it today you would lose (96.00) from holding Humacyte or give up 17.55% of portfolio value over 90 days. Humacyte is currently does not generate positive expected returns and assumes 6.5312% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Humacyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Humacyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Humacyte, and traders can use it to determine the average amount a Humacyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0165
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HUMA |
Estimated Market Risk
| 6.53 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Humacyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Humacyte by adding Humacyte to a well-diversified portfolio.
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 595 M | ||||
| Shares Outstanding | 128.67 M | ||||
| Price To Earning | 18.04 X | ||||
| Price To Book | 30.28 X | ||||
| Price To Sales | 153.91 X | ||||
| Gross Profit | 1.56 M | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Cash And Equivalents | 189.04 M | ||||
| Cash Per Share | 1.84 X | ||||
| Total Debt | 58.11 M | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 17.46 X | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (1.34) X | ||||
| Market Capitalization | 598.31 M | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
About Humacyte Performance
By analyzing Humacyte's fundamental ratios, stakeholders can gain valuable insights into Humacyte's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.58) | (1.50) | |
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 1.56 M. | |
| Humacyte currently holds about 189.04 M in cash with (73.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84. | |
| Roughly 27.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: HUMA Lead Plaintiff Deadline Approaching -- Contact Robbins LLP for Information About the Class ... |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |